- Home
- MHUA vs NEUP Comparison
MHUA vs NEUP Comparison
Compare MHUA & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHUA
- NEUP
- Stock Information
- Founded
- MHUA 1990
- NEUP 1996
- Country
- MHUA China
- NEUP United States
- Employees
- MHUA N/A
- NEUP N/A
- Industry
- MHUA Medical Specialities
- NEUP
- Sector
- MHUA Health Care
- NEUP
- Exchange
- MHUA Nasdaq
- NEUP Nasdaq
- Market Cap
- MHUA 11.8M
- NEUP 12.7M
- IPO Year
- MHUA 2022
- NEUP N/A
- Fundamental
- Price
- MHUA $0.46
- NEUP $13.12
- Analyst Decision
- MHUA
- NEUP Strong Buy
- Analyst Count
- MHUA 0
- NEUP 2
- Target Price
- MHUA N/A
- NEUP $28.00
- AVG Volume (30 Days)
- MHUA 132.7K
- NEUP 76.7K
- Earning Date
- MHUA 09-19-2025
- NEUP 08-28-2025
- Dividend Yield
- MHUA N/A
- NEUP N/A
- EPS Growth
- MHUA N/A
- NEUP N/A
- EPS
- MHUA 0.40
- NEUP 0.00
- Revenue
- MHUA $96,909,642.00
- NEUP $15,662,715.00
- Revenue This Year
- MHUA N/A
- NEUP N/A
- Revenue Next Year
- MHUA N/A
- NEUP N/A
- P/E Ratio
- MHUA $1.07
- NEUP $7,628.02
- Revenue Growth
- MHUA N/A
- NEUP N/A
- 52 Week Low
- MHUA $0.25
- NEUP $2.90
- 52 Week High
- MHUA $1.24
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- MHUA 65.24
- NEUP 63.02
- Support Level
- MHUA $0.35
- NEUP $11.35
- Resistance Level
- MHUA $0.46
- NEUP $15.14
- Average True Range (ATR)
- MHUA 0.04
- NEUP 1.65
- MACD
- MHUA 0.00
- NEUP 0.30
- Stochastic Oscillator
- MHUA 73.33
- NEUP 74.66
About MHUA Meihua International Medical Technologies Co. Ltd.
Meihua International Medical Technologies Co Ltd is engaged in providing disposable medical devices. It serves hospitals, pharmacies, medical institutions, and medical equipment companies. Its product offerings include a Disposable Medical mask, Disposable ID Bracelet, Disposable Artificial Anal bag, Disposable Catheter, and Electonic pump among others.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.